[Federal Register Volume 59, Number 89 (Tuesday, May 10, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-11161]


[[Page Unknown]]

[Federal Register: May 10, 1994]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes Of Health

 

Prospective Grant of Exclusive License: Anti-viral Agents F-ddA 
and F-ddI Useful in the Treatment of Acquired Immunodeficiency Syndrome 
(AIDS)

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive world-wide license to practice the inventions embodied in 
U.S. Patent Application SN 07/762,082 (FWC of 07/288,652, CIP of 07/
039,402) entitled ``Acid Stable Purine Dideoxynucleosides Active 
Against The Cytopathic Effects Of Human Immunodeficiency Virus'' and 
U.S. Patent Application SN 07/556,713 entitled ``2'-Fluorofuranosyl 
Derivatives And Novel Method Of Preparing 2'-Fluoropyrimidine and 2'-
Fluoropurines'' and corresponding foreign patent applications to U.S. 
Bioscience, Inc. of West Conshohocken, Pennsylvania. The patent rights 
in these inventions have been assigned to the United States of America.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
It is anticipated that this license may be limited to the field of 
treatment of human immunodeficiency virus (HIV) infection in humans 
using 9-(2,3 dideoxy-2-fluoro--Dthreo-pentofuranosyl)-adenine 
(F-ddA) and 9-(2,3 dideoxy-2fluoro--D-threo-pentofuranosyl)-
hypoxanthine (F-ddI). This prospective exclusive license may be granted 
unless within 60 days from the date of this published notice, NIH 
receives written evidence and argument that establishes that the grant 
of the license would not be consistent with the requirements of 35 
U.S.C. 209 and 37 CFR 404.7.
    U.S. Patent Application SN 07/762,082 describes novel acidstable 
2#-fluoropurine dideoxynucleosides that have been shown to inhibit HIV 
reverse transcriptase and the cytopathic effects of HIV in vitro and 
are thus are expected to be useful in the treatment of HIV-infection. 
These 2#-fluoropurine dideoxynucleosides withstand the acidic 
conditions in the stomach and may be orally administered without the 
need for antacids. U.S. Patent Application SN 07/556,713 describes an 
method of synthesis for these compounds.

ADDRESSES: Requests for a copy of these patent applications, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Steven M. Ferguson, Technology Licensing 
Specialist, Office of Technology Transfer, National Institutes of 
Health, 6011 Executive Boulevard, suite 325, Rockville, MD 20852-3804. 
Telephone: (301) 496-7735; Facsimile: (301) 402-0220; Internet: Steve 
Ferguson%NIHOD601. [email protected].
    Applications for a license filed in response to this notice will be 
treated as objections to the grant of the contemplated license. Only 
written comments and/or applications for a license which are received 
by NIH within sixty (60) days of this notice will be considered. A 
signed Confidential Disclosure Agreement will be required to receive a 
copies of the patent applications.

    Dated: May 2, 1994.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 94-11161 Filed 5-9-94; 8:45 am]
BILLING CODE 4140-01-P